128 related articles for article (PubMed ID: 33007193)
21. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
23. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
24. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
25. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
26. Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.
Zhang HM; Yan Y; Wang F; Gu WY; Hu GH; Zheng JH
Int J Clin Exp Pathol; 2014; 7(9):6079-84. PubMed ID: 25337254
[TBL] [Abstract][Full Text] [Related]
27. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
28. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
[TBL] [Abstract][Full Text] [Related]
31. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
32. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
33. [Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia].
Kamalov AA; Samokhodskaya LM; Karpov VK; Okhobotov DA; Mamedov VN
Urologiia; 2019 Jun; (2):73-81. PubMed ID: 31162906
[TBL] [Abstract][Full Text] [Related]
34. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.
Gondek T; Szajewski M; Szefel J; Aleksandrowicz-Wrona E; Skrzypczak-Jankun E; Jankun J; Lysiak-Szydlowska W
Biomed Res Int; 2014; 2014():102478. PubMed ID: 24783193
[TBL] [Abstract][Full Text] [Related]
36. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
[TBL] [Abstract][Full Text] [Related]
37. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
38. Plasma vascular endothelial growth factors A and C in patients undergoing prostatic biopsy and TURP for suspected prostatic neoplasia.
Singh A; Gautam KA; Dalela D; Sankhwar S; Natu S; Sankhwar P; Srivastava A
Asian Pac J Cancer Prev; 2013; 14(3):2053-8. PubMed ID: 23679318
[TBL] [Abstract][Full Text] [Related]
39. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
40. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Martin AA; Clejan S
J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
